US Esophageal Cancer Market: How Is HER2 Testing Creating Precision...

a adăugat un sunet Health

2026-05-12 10:12:55 -

US Esophageal Cancer Market: How Is HER2 Testing Creating Precision Oncology Opportunities?

HER2 testing and targeted therapy in esophageal/GEJ adenocarcinoma — the trastuzumab (Herceptin) approval for HER2-positive gastric/GEJ cancer and the expanding HER2-directed pipeline — creates the precision oncology commercial dimension, with the US Esophageal Cancer Market reflecting HER2-targeted therapy as an important commercial market dimension. HER2 prevalence in esophageal...

0 Commentarii 0 Distribuiri 49 Views 0 previzualizare